Should dose-intense immunochemotherapy be the new standard of care for primary CNS lymphoma?
University of Washington, Seattle, WA.
Marc C
MC
Chamberlain
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male